I. Tartakovsky

A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin.

E. Jaffee, S. Piantadosi, A. Wolff, 2004, Human gene therapy.

Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation

E. Jaffee, J. Nemunaitis, E. Sugar, 2008, Clinical Cancer Research.

K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients (PTS) with residual disease on imatinib mesylate (IM).

J. Kowalski, B. Smith, Y. Kasamon, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

K562/GM-CSF Vaccination Reduces Tumor Burden, Including Achieving Molecular Remissions, in Chronic Myeloid Leukemia (CML) Patients with Residual Disease on Imatinib Mesylate (IM).

J. Kowalski, K. Murphy, Richard J. Jones, 2005 .

A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation

K. Lillemoe, J. Cameron, R. Abrams, 2011, Annals of surgery.

A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas

R. Hruban, E. Jaffee, S. Piantadosi, 2007 .